pharmaphorum
MARCH 8, 2022
To celebrate International Women’s Day, we speak to design engineer at Envair Technology Darina Shopova; managing director, UK & ROI at Healthcare Business of Merck Doina Ionescu; and vice president of clinical development, medical, and regulatory affairs, Novo Nordisk UK Avideh Nazeri about their careers, how their field is progressing and how the industry can encourage more women and girls to pursue roles in STEM.
Pharma Tutor
MARCH 8, 2022
Rice Ferment Filtrate in Cosmetics. About Author. Vinay Kumar Singh. . Head-Formulation. Kumar Organic Products Research Centre Pvt. Ltd., Bengaluru. admin. Tue, 03/08/2022 - 17:07. Tags. Articles.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 8, 2022
There is no evidence that vaccination with either the Pfizer/BioNTech or Moderna’s mRNA-based COVID-19 vaccines led to the death of patients, says a study by researchers at the Centres for Disease Control and Prevention (CDC). The analysis of data from US adverse event monitoring systems comes from the first six months after vaccination with the two vaccine started in the US, a period in which just under 4,500 people died after being vaccinated and almost 300 million doses were administere
Outsourcing Pharma
MARCH 8, 2022
The drug company has renewed its arrangement with the artificial intelligence specialist, centered on using AI to improve understanding of the immune system.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MARCH 8, 2022
The results of Gilead’s much-anticipated TROPiCS-02 study of Trodelvy are in, and while the company says top-line data are positive, its guarded stance has rung some alarm bells. In the study, Trodelvy (sacituzumab govitecan) met its objective of reducing progression-free survival in patients with HR-positive, HER2-negative metastatic breast cancer who received multiple lines of prior treatment – including endocrine drugs, CDK4/6 inhibitors and two to four lines of chemotherapy.
Outsourcing Pharma
MARCH 8, 2022
Integrated research organization Circuit Clinical will standardize its decentralized operations with Medidataâs RAVE and myMedidata technological offerings.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Outsourcing Pharma
MARCH 8, 2022
The pharmaceutical company and the digital therapeutics specialist are joining forces to help accelerate the expansion of various digital health solutions.
pharmaphorum
MARCH 8, 2022
Moderna has unveiled plans to start clinical trials of mRNA-based vaccines for 15 infectious diseases that pose the biggest public health risks around the world – including HIV, malaria and tuberculosis – by 2025. The programme is targeting pathogens that have been deemed by the World Health Organization (WHO) and Coalition for Epidemic Preparedness Innovations (CEPI) to have the greatest impact on the health of people around the world.
Pharma Times
MARCH 8, 2022
Novartis and Voyager Therapeutics announce partnership to develop gene therapies for neurological disorders
pharmaphorum
MARCH 8, 2022
Voyager Therapeutics has signed another big pharma partner for its TRACER adeno-associated virus (AAV) vector technology, designed to improve the safety of gene therapies, with Novartis taking an option on three neurological disease programmes. Novartis is paying $54 million upfront to buy in to these three – with another two targets in reserve – and the total value of the deal could reach $1.7 billion including fees and milestones.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
MARCH 8, 2022
Advanced Therapy Medicinal Product classification for Ixaka Ltd’s chemically encapsulated lentiviral vector
Expert insights. Personalized for you.
98 
Let's personalize your content